𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Low-dose vaccination against hepatitis B in children: One-year follow-up

✍ Scribed by Mr. Alexander Milne; Mary Dimitrakakis; Carolyn Campbell; Ron Lucas; Geoff Allwood; Paul Goldwater; Neil Pearce; Saul Krugman

Publisher
John Wiley and Sons
Year
1987
Tongue
English
Weight
321 KB
Volume
22
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis

Six hundred forty-three children, negative for markers of hepatitis B virus (HBV) infections, were given three X 2-micrograms doses of Merck, Sharp and Dohme (MSD) plasma derived hepatitis B vaccine (H-B-Vax) at monthly intervals. Twelve months after the first dose of vaccine, antibody to hepatitis B surface antigen (anti-HBs) was detected in 89% of children by radioimmunoassay (RIA) and in 83% by enzyme immunoassay (EIA). Seroconversion rates and anti-HBs titres were significantly greater in 1-4-year-olds than in older children (p less than 0.01). Eighteen children with no anti-HBs or other markers of HBV at this time were given 10 micrograms of vaccine and tested one month later. Seventeen developed anti-HBs, 12 at levels consistent with an anamnestic response. Forty-nine HBV-marker-negative children seroconverted for antibody to hepatitis B core antigen (anti-HBc) in the 8-month period before or the 12-month period following vaccination. Forty-six of these children were positive for anti-HBs, and one has been confirmed as a chronic carrier of hepatitis B surface antigen (HBsAg). Three cases of clinical hepatitis B in children have been seen in the community since the vaccination programme began. Two of these were amongst the estimated 5% of children who were not vaccinated. The third was in a vaccinee and occurred 4 1/2 months after the last dose of vaccine.(ABSTRACT TRUNCATED AT 250 WORDS)

📜 SIMILAR VOLUMES

Twelve-year follow-up of a prospective r
Twelve-year follow-up of a prospective randomized trial of hepatitis b recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children
✍ Man-Fung Yuen; Wei-Ling Lim; Chi-Chung Cheng; Shiu-Kam Lam; Ching-Lung Lai 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 49 KB

A total of 318 children were prospectively randomized in group 1 with two 5-g doses of recombinant vaccine given at 0 and 1 month; in group 2 with three 5-g doses of recombinant vaccine given at 0, 1, and 6 months; or in group 3 with three doses of plasma-derived vaccine given at 0, 1, and 6 months.

Immunogenicity of low doses of hepatitis
Immunogenicity of low doses of hepatitis B vaccine in children: A study in 650 New Zealand children
✍ Alexander Milne; Mary Dimitrakakis; Geoffrey Allwood; Ron Lucas; Chris Moyes; Ne 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 392 KB

Six hundred and fifty New Zealand children from 2-12 years of age were vaccinated three times with 2 mcg intramuscular (IM) doses of Merck Sharp and Dohme plasma-derived hepatitis B vaccine (H-B-Vax), at 0, 1, and 6 months, and tested 2-3 months later for antibody to hepatitis B surface antigen (ant

Very low dose hepatitis B vaccination in
Very low dose hepatitis B vaccination in the newborn: Anamnestic response to booster at four years
✍ Dr. C. D. Moyes; A. Milne; J. Waldon 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 236 KB

## Abstract Seventy‐eight children who had received three very low doses (1 or 2 μg) of Merck, Sharp, and Dohme (MSD) plasma‐derived vaccine (PDV) in early infancy were followed to approximately four years of age. Of the 70 who had responded to the initial course of vaccine with measurable anti‐HBs

Antibody persistence and immune memory i
Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: Long-term follow-up at 15 years
✍ Koen Van Herck; Jeanne-Marie Jacquet; Pierre Van Damme 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 202 KB

## Abstract Long‐term persistence of vaccine‐induced immune response in adults was assessed annually for 15 years following primary immunization with a two‐dose inactivated hepatitis A vaccine. In 1992, 119 and 194 subjects aged 17–40 years and naïve for hepatitis A virus (HAV) were enrolled in two

Hepatitis B vaccine: Immunogenicity and
Hepatitis B vaccine: Immunogenicity and follow-up including two year booster doses in high-risk health care personnel in a London teaching hospital
✍ Dr. Elizabeth A. Fagan; Philippa Tolley; Heather M. Smith; Roger Williams; Adria 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 457 KB

One hundred forty-four adult health care personnel (aged 18-62 years, median 33 years) considered at high risk of future HBV infection were vaccinated with a plasma-derived hepatitis B vaccine (20 pg HBVax at 0, 1, and 6 months) and followed-up for 2 years. Anti-HBs was present in only 6.9% prior to

Long-term persistence of antibodies indu
Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults
✍ P. Van Damme; G. Leroux-Roels; B. Law; F. Diaz-Mitoma; I. Desombere; F. Collard; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 202 KB 👁 1 views

## Abstract It is important to monitor the long‐term persistence of antibodies induced by vaccination. Four cohorts were followed for their long‐term immunity after vaccination with a combined hepatitis A and B vaccine (Twinrix; SmithKline Beecham Biologicals, Rixsenart, Belgium). Two cohorts of ad